EVP 0962

Drug Profile

EVP 0962

Alternative Names: EVP-0015962; EVP-0962

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator EnVivo Pharmaceuticals
  • Developer FORUM Pharmaceuticals
  • Class Nootropics; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Jun 2016 Discontinued - Phase-II for Alzheimer's disease in USA (PO)
  • 03 Oct 2015 No recent reports of development identified - Phase-II for Alzheimer's disease in USA (PO)
  • 02 Apr 2014 EnVivo Pharmaceuticals is now called FORUM Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top